A Prospective, Open-label, Dose-escalation, Single-center, Phase I Trial to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin)
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GC 1102 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 13 Oct 2017 Status changed from recruiting to completed.
- 12 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.